Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells

Acta Pharmacologica Sinica

Volumn 33, Issue 6, 2012, Pages 823-831

  Punfa, Wanisa ^a   Yodkeeree, Supachai ^a   Pitchakarn, Pornsiri ^a   Ampasavate, Chadarat ^b   Limtrakul, Pornngarm ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

anticancer drug; cervical cancer; curcumin; multidrug resistance; nanoparticle; P glycoprotein; targeting drug delivery

Indexed keywords

CURCUMIN; GLYCOPROTEIN P ANTIBODY; NANOCARRIER; POLYGLACTIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG RELEASE; DRUG SPECIFICITY; DRUG UPTAKE; EPIFLUORESCENCE MICROSCOPY; FLOW CYTOMETRY; PARTICLE SIZE; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; ZETA POTENTIAL;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CERVIX UTERI; CURCUMIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTIC ACID; NANOPARTICLES; P-GLYCOPROTEIN; PARTICLE SIZE; POLOXAMER; POLYGLYCOLIC ACID; UTERINE CERVICAL NEOPLASMS;

EID: 84862511071     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.34     Document Type: Article

References (38)

1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
3. Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 2005; 117: 670-82.
4. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother Pharmacol 2004; 54: 525-30.
5. Pitchakarn P, Ohnuma S, Pintha K, Pompimon W, Ambudkar SV, Limtrakul P. Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. J Nutr Biochem 2012; 23: 76-84.
6. Chanmahasathien W, Ampasavate C, Greger H, Limtrakul P. Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance. Phytomedicine2011; 18: 199-204.
7. Romiti N, Tongiani R, Cervelli F, Chieli E. Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci 1998; 62: 2349-58.
8. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002; 64: 573-82.
9. Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006; 6: 259-70.
10. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 2004; 68: 2043-52.
11. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
12. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010; 351: 19-29.
13. Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, Delie F. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 mmunonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci 2009; 38: 230-7.
14. Cheng Y, C Samia A, Meyers JD, Panagopoulos I, Fei B, Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 2008; 130: 10643-7.
15. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004; 8: 335-53.
16. Lei T, Srinivasan S, Tang Y, Manchanda R, Nagesetti A, Fernandez- Fernandez A, et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine 2011; 7: 324-32.
17. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004; 12: 461-71.
18. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007; 120: 18-26.
19. Debotton N, Zer H, Parnes M, Harush-Frenkel O, Kadouche J, Benita S. A quantitative evaluation of the molecular binding affinity between a monoclonal antibody conjugated to a nanoparticle and an antigen by surface plasmon resonance. Eur J Pharm Biopharm 2010; 74: 148-56.
20. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000; 113: 355-63.
21. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999; 5: 3352-6.
22. Wang G, Uludag H. Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opin Drug Deliv 2008; 5: 499-515.
23. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009; 29: 3867-75.
24. Bennewitz MF, Saltzman WM. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics 2009; 6: 323-36.
25. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): A novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5: 3.
26. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010; 79: 330-8.
27. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, et al. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem 2011; 59: 9280-9.
28. Guerrouache M, Karakasyan C, Gaillet C, Canva M, Millot MC. Immobilization of a functionalized poly(ethylene glycol) onto betacyclodextrin- coated surfaces by formation of inclusion complexes: Application to the coupling of proteins. J Appl Polym Sci 2006; 100: 2362-70.
29. Chittasupho C, Xie SX, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009; 37: 141-50.
30. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009; 37: 223-30.
31. Wieder ME, Hone DC, Cook MJ, Handsley MM, Gavrilovic J, Russell DA. Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a 'Trojan horse'. Photochem Photobiol Sci 2006; 5: 727-34.
32. Iangcharoen P, Punfa W, Yodkeeree S, Kasinrerk W, Ampasavate C, Anuchapreeda S, et al. Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment. Arch Pharm Res 2011; 34: 1679-89.
33. Sa G, Das T. Anti cancer effects of curcumin: cycle of life and death. Cell Div 2008; 3: 14.
34. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-18.
35. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009; 86: 215-23.
36. Gou M, Men K, Shi H, Xiang M, Zhang J, Song J, et al. Curcuminloaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 2011; 3: 1558-67.
37. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-96.
38. Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti- CD20 (Mabthera) coupled nanoparticles. Int J Pharm 2007; 331: 190-6.